| gTLD | Full Legal Name | E-mail suffix | Detail | | .CIALIS | Eli Lilly and Company | fairwindspartners.com | View |
18.2 How do you expect that your proposed gTLD will benefit registrants, Internet users, and others?
Lilly believes that the proposed .CIALIS gTLD has the potential to offer the following benefits to Internet users and consumers:
-Establish a trusted source of information for the millions of patients, partners, and health care professionals who use or are involved with Lilly’s Cialis product and related services, as well as for investors and others seeking information regarding Lilly’s Cialis product, Lilly’s affiliates and subsidiaries, and their products and services, and for the general Internet user population;
-Provide Lilly and its qualified subsidiaries and affiliates with short and memorable Internet addresses related to the Cialis product;
-Develop a potential platform for secure access to Cialis-related information for consumers, in order to minimize the likelihood of accessing counterfeit or illegal versions of the medicine that pose a risk to patient safety; and
-Potentially provide Lilly and its qualified subsidiaries and affiliates with an online single source-identifying function related to the Cialis product for its current and future customers around the globe.
Currently Lilly operates a number of websites that correspond to the various geographic regions in which it has a substantial presence. Lilly uses a combination of second-level and top-level domain names in connection with these websites. Lilly believes that the .CIALIS gTLD could help to provide a more intuitive source-identifying function for its current and future customers around the globe.
18.2.1 What is the goal of your proposed gTLD in terms of areas of specialty, service levels, or reputation?
The primary mission and purpose of the .CIALIS gTLD is to provide a trusted, hierarchical, and intuitive virtual platform to deliver content and information about Lillyʹs business, the Cialis product, and services related to that product. As Lilly’s business model continues to evolve, it is the company’s desire to pursue and develop new opportunities to provide its online content and services to consumers in the U.S. and internationally on a variety of platforms, including the Internet and mobile devices. Given that customers increasingly request access to information about Lilly and its products through a variety of channels, including via websites using domain names, Lilly believes that the .CIALIS gTLD has the potential to provide an innovative, virtual avenue to Lilly that will deepen and broaden the companyʹs relationship with patients, partners, health care professionals, and other stakeholders.
Most importantly, Lilly will be able to provide access to Cialis product information and other related online content in a namespace devoid of cybersquatting, sales of counterfeit or illegal medicines, and other malicious activities. Patient safety is paramount to Lilly and it is anticipated that the .CIALIS gTLD will help further that goal. The .CIALIS gTLD has the potential to offer Internet users a safe and intuitive means of accessing authorized content from Lilly and its qualified subsidiaries and affiliates related to the Cialis product.
18.2.2 What do you anticipate your proposed gTLD will add to the current space, in terms of competition, differentiation, or innovation?
As a branded gTLD, the primary driving factors behind the .CIALIS gTLD are differentiation and innovation. The success of .CIALIS will not be measured by the number of domain names registered, but rather by the levels of consumer recognition and trust that are placed in the gTLD. More specifically, Lilly will be able to communicate to Internet users that the .CIALIS namespace provides a safe and trusted place to find information about Lilly’s Cialis product and related services.
18.2.3 What goals does your proposed gTLD have in terms of user experience?
Lilly believes that the .CIALIS gTLD will provide a single, trusted experience for the millions of consumers worldwide who use the Cialis product and related services, as well as for those seeking information related to Cialis, such as investors, health care professionals, partners, and patients. In addition to providing consumers with short and intuitive domain names to remember, the .CIALIS gTLD will indicate to Internet users that the domains and website content are owned and controlled by Lilly and its qualified subsidiaries and affiliates, thus demonstrating to users that the information is safe from spam and other potentially infringing or harmful content.
The initial use of the .CIALIS gTLD will be primarily defensive in nature, with Lilly registering a limited number of second-level domain names. This initial use will provide Lilly’s IT and security personnel with an opportunity to test access to Lilly’s Cialis-related websites, and ensure interoperability with various software and Web-⁄mobile-based applications. Once the appropriate security and stability issues have been satisfactorily addressed, Lilly will likely begin allocating domain names for internal corporate use and may redirect new .CIALIS domain names to preexisting content. This phased rollout will likely take place over a multi-year period, and is subject to change depending upon a range of external factors.
During this same period of time, Lilly will evaluate potential strategies for use of the .CIALIS gTLD in other ways that will advance Lilly’s corporate mission and goals.
18.2.4 Provide a complete description of the applicant’s intended registration policies in support of the goals listed above.
Lilly currently intends for the .CIALIS gTLD to be exclusively used by Lilly and its qualified subsidiaries and affiliates, at least for the first three years of operation. By virtue of its corporate relationship with those entities, Lilly will be able to require that the use of the .CIALIS gTLD is in support of the goals listed above. In the event of an expansion to approved partners and others as described above, Lilly will require that such use of the .CIALIS gTLD supports the goals listed above by means of the terms and conditions of the relevant agreements that such other parties will execute.
18.2.5 Will your proposed gTLD impose any measures for protecting the privacy or confidential information of registrants or users? If so, please describe any such measures.
As a global pharmaceutical company, Lilly recognizes that this is an evolving area of law. Due to the fact that every domain name will be registered to Lilly and its qualified subsidiaries and affiliates, at least for the first three years of operation, and because the .CIALIS gTLD will be identified with Lilly, the company has a vested interest in ensuring that accurate and current domain name information is readily available in connection with each .CIALIS domain name. All private or confidential information will be protected as required by applicable law.
Lilly will ensure that the operation of the .CIALIS gTLD will be consistent with Lillyʹs Privacy Policy available here: http:⁄⁄www.lilly.com⁄privacy⁄Pages⁄default.aspx.
In addition, Lilly intends to incorporate contractual language in its Registry-Registrar Agreement (RRA) modeled after language that has been included in the template Registry Agreement and that has been successfully utilized by existing ICANN gTLD Registry Operators.
The template Registry Agreement states, “Registry Operator shall (i) notify each ICANN-accredited registrar that is a party to the registry-registrar agreement for the TLD of the purposes for which data about any identified or identifiable natural person (“Personal Data”) submitted to Registry Operator by such registrar is collected and used under this Agreement or otherwise and the intended recipients (or categories of recipients) of such Personal Data, and (ii) require such registrar to obtain the consent of each registrant in the TLD for such collection and use of Personal Data. Registry Operator shall take reasonable steps to protect Personal Data collected from such registrar from loss, misuse, unauthorized disclosure, alteration or destruction. Registry Operator shall not use or authorize the use of Personal Data in a way that is incompatible with the notice provided to registrars.”
18.2.6 Describe whether and in what ways outreach and communications will help to achieve your projected benefits.
As noted above, Lilly’s driving factor in securing the .CIALIS gTLD in ICANN’s first gTLD application round is precautionary in nature, and while Lilly sees the potential for this gTLD to play a large role in Lilly’s future online strategic initiatives, there are a number of unanswered questions concerning consumer recognition, the adoption of new gTLDs, and the response from search engines in the marketplace that will influence both the usage of the gTLD and communications about that usage.
Notwithstanding this, Lilly plans to start using .CIALIS domains initially as redirects to some existing .COM websites. Lilly also plans to carefully review the release of new gTLDs by others, the response from search engines to new gTLDs, and consumer perception. As the marketplace evolves, Lilly will reasonably invest in outreach and communication as needed to help its consumers and partners to continue to interact with Lilly’s Cialis-related content in a simplified and more intuitive manner.
| gTLD | Full Legal Name | E-mail suffix | Detail | | .ABBOTT | Abbott Laboratories | fairwindspartners.com | View |
18.2 How do you expect that your proposed gTLD will benefit registrants, Internet users, and others?
Abbott believes that the proposed .ABBOTT gTLD has the potential to offer the following benefits to Internet users and consumers:
-Establish a trusted source of information for the millions of consumers who use Abbott’s products and services, for investors and third parties seeking information, and for the general Internet user population;
-Provide Abbott and its qualified subsidiaries and affiliates with short and memorable Internet addresses; provide improved and integrated navigation to products, services, advertising campaigns, public interest content, public awareness initiatives, etc.; and minimize the cost and need for defensive registrations because domain names will only be allocated by Abbott within the .ABBOTT gTLD to Abbott and its subsidiaries and affiliates; and
-Develop a potential platform for secure access to Abbott products and information to consumers, in order to minimize the potential for counterfeit or infringing products and services.
- Increase awareness of Abbott and its diversified portfolio of products and services.
Currently Abbott operates a number of websites that correspond to the various geographic regions in which it has a substantial presence. Abbott uses a combination of second-level and top-level domain names in connection with these websites. A representative sampling of Abbott websites registered in ccTLDs and well as those that incorporate geographical identifiers into domain names include:
www.Abbottinmunologia.com.ar
www.AbbottAustralasia.com.au
www.Abbott.com.cn
www.Abbott.dk
www.Abbott.fr
www.Abbott.de
www.Abbott.co.in
www.Abbott.ie
www.AbbottItalia.com
www.Abbottvascular.jp
www.Abbottdiabetescare.no
www.Abbott.es
www.Abbott.co.uk
www.AbbottNutritionUK.com
www.Abbott.ca
www.Abbott.us
Abbott believes that the .ABBOTT gTLD can provide an online single-source identifying construct that will be easier for its current and future customers around the globe, instead of the current approach that Abbott is forced to resort to as it expands into different markets around the world.
18.2.1 What is the goal of your proposed gTLD in terms of areas of specialty, service levels, or reputation?
The primary mission and purpose of the .ABBOTT gTLD is to provide a trusted, hierarchical, and intuitive virtual platform to deliver content and information about Abbottʹs business, focus, products and services. As Abbott continues to grow, it is the company’s desire to pursue and develop new opportunities to market its online content and products to consumers, in the U.S. and internationally, on a variety of platforms. Given that customers are increasingly requesting access to Abbott and its products and services through a variety of channels, including via domain names, Abbott believes that the .ABBOTT gTLD has the potential to provide an innovative, virtual avenue to Abbott products and services that will deepen and broaden the companyʹs relationship with consumers.
Most importantly, Abbott will be able to provide access to its products and online content in a namespace void of piracy, cybersquatting, and other malicious activities. Providing consumers with a reliable online experience is paramount to Abbott, and the .ABBOTT gTLD will be used to further that goal.
18.2.2 What do you anticipate your proposed gTLD will add to the current space, in terms of competition, differentiation, or innovation?
As a branded gTLD, the primary driving factors behind the .ABBOTT gTLD are differentiation and innovation. The success of .ABBOTT will not be measured by the number of domain names registered, but rather by the levels of consumer recognition and trust that are placed in the gTLD. Using this as a benchmark, Abbott will continue to strive to increase these until they rise to the levels of those found in the .EDU and .GOV gTLDs. More specifically, Abbott will be able to communicate to Internet users that the .ABBOTT namespace provides a safe and trusted place to find information about the company and its products and services.
18.2.3 What goals does your proposed gTLD have in terms of user experience?
Abbott believes that the .ABBOTT gTLD will provide a single, trusted ecosystem experience for the millions of consumers worldwide who use the company’s products and services, as well as for those seeking information provided by Abbott, such as investors, medical providers, insurers and business partners. In addition to providing consumers with short, memorable, and intuitive domain names, the .ABBOTT gTLD will indicate to consumers that the domains and content are owned and controlled by Abbott and its qualified subsidiaries and affiliates.
Abbott expects the initial use of the .ABBOTT gTLD to involve Abbott registering a limited number of second-level domain names. This initial use will provide Abbott’s IT and security personnel with the ability to run a number of tests to ensure seamless and secure access to the Abbott website, and interoperability with various software and Web-⁄mobile-based applications. Once the appropriate security and stability issues have been satisfactorily addressed, Abbott will likely begin allocating domain names for internal corporate use and may redirect new .ABBOTT domain names to pre-existing content. This phased rollout will likely take place over a multi-year period, but is subject to change depending upon a range of external factors.
During this same period of time, Abbott will continue to evaluate potential strategies for use of the .ABBOTT gTLD in other ways that will advance Abbott’s corporate mission and goals.
18.2.4 Provide a complete description of the applicant’s intended registration policies in support of the goals listed above.
Abbott currently intends for the .ABBOTT gTLD to be exclusively used by Abbott and its qualified subsidiaries and affiliates. Because of this condition, any registration and use requirements are more appropriately vested in the corporate agreements between Abbott Laboratories and its subsidiaries and affiliates, and not in a domain name registration agreement.
Notwithstanding this, Abbott will incorporate all required ICANN consensus policies and other legal⁄policy requirements imposed on new gTLD applicants into the terms and conditions of the domain name registration agreement that each potential partner will execute.
18.2.5 Will your proposed gTLD impose any measures for protecting the privacy or confidential information of registrants or users? If so, please describe any such measures.
As a global, diversified healthcare company, Abbott recognizes that this is an evolving area of law in which there is no international standard. However, due to the fact that every domain name will be registered to Abbott or its qualified subsidiaries and affiliates, the company has a vested interest in ensuring that accurate and current domain registration name information is readily available in connection with each .ABBOTT domain name. For the .ABBOTT gTLD, all private and confidential information will be protected.
Abbott will ensure that the operation of the .ABBOTT gTLD will be consistent with the local privacy regulations of Abbott and its qualified subsidiaries and affiliates. For the Statement of Privacy Principles in the U.S. see: http:⁄⁄www.abbott.com⁄global⁄url⁄content⁄en_US⁄0:0⁄general_content⁄General_Content_00029.htm.
In addition, Abbott intends to incorporate contractual language in its Registry-Registrar Agreement (RRA) modeled after language that has been included in the template Registry Agreement and that has been successfully utilized by existing ICANN gTLD Registry Operators. Specifically, Abbott shall notify Registrar of the purposes for which Personal Data submitted to Registry Operation by Registrar is collected, the intended recipients (or categories of recipients) of such Personal Data, and the mechanism for access to and correction of such Personal Data. Registry Operator shall take reasonable steps to protect Personal Data from loss, misuse, unauthorized disclosure, alteration or destruction. Registry Operator shall not use or authorize the use of Personal Data in a way that is incompatible with the notice provided to registrars. Registry Operator may from time to time use the demographic data collected for statistical analysis, provided that this analysis will not disclose individual Personal Data and provided that such use is compatible with the notice provided to registrars regarding the purpose and procedures for such use.
18.2.6 Describe whether and in what ways outreach and communications will help to achieve your projected benefits.
As noted above, Abbott’s driving factor in securing the .ABBOTT gTLD in ICANN’s first gTLD application round is precautionary in nature, and while Abbott sees the potential for this gTLD to play a large role in Abbott’s future online strategic initiatives, there are a number of unanswered questions concerning consumer recognition, the adoption of new gTLDs, and the response from search engines in the marketplace that will influence the usage of the gTLD and communication about that usage.
Notwithstanding this, Abbott plans to start using .ABBOTT domains initially as redirects to existing .COM websites. Abbott also plans to carefully review the release of new gTLDs by others, the response from search engines to branded gTLDs, and consumer perception. As the marketplace evolves, Abbott will invest in outreach and communication as needed to ensure that its consumers and partners continue to interact with Abbott content in a simplified and efficient manner.